Pfizer Oncology Deal History & Licensing Activity
Pfizer Oncology is a large pharma headquartered in US. Over the past three years, Pfizer Oncology has been involved in 4 licensing and acquisition transactions, with a primary focus on S1pModulator (1 deal). The company currently has 11 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
2
Active Trials
11
Top Modality
S1pModulator
Focus Area
Solid Tumors
Pfizer Oncology Pipeline Focus
Therapeutic areas and modalities where Pfizer Oncology is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Pfizer Oncology Strategic Signals
Key indicators of Pfizer Oncology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Pfizer Oncology Clinical Pipeline
Pfizer Oncology has 11 active clinical trials across 4 development phases.
1
Unknown
2
Phase 1
7
Phase 2
1
Phase 3
See How Your Asset Matches Pfizer Oncology's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
S1pModulator Benchmarks
Upfront, milestone, and royalty benchmarks for s1pmodulator deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Pfizer Oncology Licensing & Deal Activity
Pfizer Oncology is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Pfizer Oncology ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Pfizer Oncology include Solid Tumors (6 deals and trials), Hematological Malignancies (4 deals and trials), Gastroenterology (2 deals and trials), and Oncology (1 deal and trial). In terms of modality, Pfizer Oncology has shown particular interest in s1pmodulator, bispecific antibodies, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Pfizer Oncology and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Pfizer Oncology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.